Mirum Pharmaceuticals, Inc.
MIRM
Peringkat dalam Saham
#3220
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to... Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California.
Harga Saham
$85.31
Kapitalisasi Pasar
$5.54B
Perubahan (1 hari)
3.73%
Perubahan (1 tahun)
16.82%
Negara
US
Perdagangan Mirum Pharmaceuticals, Inc. (MIRM)
Kategori
Healthcare
Rasio P/S untuk Mirum Pharmaceuticals, Inc. (MIRM)
Rasio P/S per October 2026 TTM: 8.40
Menurut laporan keuangan dan harga saham terbaru dari Mirum Pharmaceuticals, Inc., rasio P/S saat ini (TTM) adalah 8.40. Pada akhir 2023, rasio P/S perusahaan adalah 6.48.
Riwayat rasio P/S untuk Mirum Pharmaceuticals, Inc. dari 2018 hingga 2026
Rasio P/S pada akhir setiap tahun
| Tahun | Rasio P/S | Mengubah |
|---|---|---|
| 2026 (TTM) | 8.40 | 44.09% |
| 2024 | 5.83 | -9.93% |
| 2023 | 6.48 | -24.37% |
| 2022 | 8.56 | -66.12% |
| 2021 | 25.27 | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | 0.00% |
| 2018 | 0.00 | 0.00% |
Rasio P/S untuk perusahaan sejenis atau pesaing
| Perusahaan | Rasio P/S | Perbedaan Rasio P/S | Negara |
|---|---|---|---|
| 10.02 | 19.31% |
US
|
|
| 40.55 | 382.73% |
US
|
|
| 3.96 | -52.85% |
AU
|
|
| - | - |
CH
|
|
| 10.15 | 20.78% |
NL
|
